203 related articles for article (PubMed ID: 36592233)
1. Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.
Kuhn EP; Pirruccello J; Boothe JT; Li Z; Tosteson TD; Stahl JE; Schwartz GN; Chamberlin MD
Breast Cancer Res Treat; 2023 Feb; 198(1):31-41. PubMed ID: 36592233
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
3. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
4. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
5. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW; Hughes TMD; Marx G; Boyages J; Rutovitz J; Hasovits C; Parasyn A; Edirimanne S; Ngui NK
Breast J; 2022; 2022():1199245. PubMed ID: 35711899
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
7. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
9. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
Barni S; Cognetti F; Petrelli F
Breast Cancer Res Treat; 2022 Jan; 191(2):477-480. PubMed ID: 34817748
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
Cheng V; Markarian A; de Lemos ML; Schaff K
J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
[TBL] [Abstract][Full Text] [Related]
11. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Thibodeau S; Voutsadakis IA
Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
13. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
14. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
15. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
Clancy C; Lynch J; OConnor P; Dowling M
Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
18. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
[TBL] [Abstract][Full Text] [Related]
19. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]